Novartis has announced a planned $23-billion investment over five years in US-based infrastructure to ensure that all key Novartis medicines for US patients will be made in the United States. The new investments will expand the company’s manufacturing, research and technology presence across 10 facilities, including seven new facilities, creating nearly 1,000 new jobs at Novartis and approximately 4,000 additional US jobs. The production capacity will cover both active pharmaceutical ingredients and biologic drug substances as well as secondary production and packaging. 

Over the next five years, Novartis says it will: 

• Establish one biomedical research innovation hub in San Diego, California, its second global R&D hub in the US;  

• Build four new manufacturing facilities in soon-to-be-determined states, including three that will make biologic drug substances, drug products, device assembly and packaging, and one facility that will make chemical drug substances, oral solids dosage forms, and packaging;  

• Build two new radioligand therapy (RLT) manufacturing facilities in Florida and Texas; and  

• Expand three RLT manufacturing facilities in Indianapolis, Indiana, Millburn, New Jersey, and Carlsbad, California.  

With these investments, Novartis says it will have manufacturing capacity in the US for all its core technology platforms, including small molecules and biologics. Novartis says it already manufactures its most innovative, advanced therapies in the US for patients in the US and globally, including gene and cell therapies and RLT manufacturing. This new investment will bring internal manufacturing of the company’s siRNA technology to the US for the first time, which reflects a commitment to increase US manufacturing across its main therapeutic areas: oncology, immunology, neuroscience, and cardiovascular, renal and metabolic diseases. “With the new manufacturing capacity, Novartis will be able to produce 100% of its key medicines end-to-end in the US, a significant increase from current levels,” said the company in an April 10, 2025, press release.

The investment includes a newly planned $1.1-billion research hub in San Diego. The new complex, expected to open between 2028 and 2029, will serve as the center of the Novartis West Coast Biomedical Research presence, complementing existing hubs in Cambridge, Massachusetts, and Basel, Switzerland. 

In addition, the company will be expanding RLT manufacturing with new facilities in Florida and Texas. To support growing demand for RLTs in the US, Novartis has already expanded production capabilities in Millburn, New Jersey, and a facility in Indianapolis, Indiana, and is currently building a third US RLT manufacturing facility in Carlsbad, California.  

Over the next five years, the company says that its total investment in its US operations is expected to be nearly $50 billion. 

Source: Novartis